Biogen Inc. (NASDAQ:BIIB) Forecasted to Post FY2026 Earnings of $29.12 Per Share

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at Oppenheimer issued their FY2026 EPS estimates for shares of Biogen in a research report issued to clients and investors on Tuesday, January 11th. Oppenheimer analyst J. Olson anticipates that the biotechnology company will post earnings of $29.12 per share for the year. Oppenheimer currently has a “Outperform” rating and a $350.00 target price on the stock.

Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, October 19th. The biotechnology company reported $4.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.09 by $0.68. The firm had revenue of $2.78 billion for the quarter, compared to analyst estimates of $2.67 billion. Biogen had a return on equity of 28.36% and a net margin of 13.93%. The company’s revenue for the quarter was down 17.7% on a year-over-year basis. During the same period in the previous year, the company posted $8.84 earnings per share.

BIIB has been the topic of a number of other reports. UBS Group cut their price target on Biogen from $390.00 to $335.00 in a report on Monday, January 3rd. Bank of America lowered their price target on Biogen from $275.00 to $245.00 and set a “neutral” rating on the stock in a research report on Friday. Needham & Company LLC lowered their price target on Biogen from $386.00 to $328.00 and set a “buy” rating on the stock in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $453.00 price target on shares of Biogen in a research report on Thursday, October 21st. Finally, TheStreet downgraded Biogen from a “b-” rating to a “c+” rating in a research report on Monday, October 4th. Seventeen equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Biogen has a consensus rating of “Buy” and a consensus price target of $322.99.

Shares of Biogen stock opened at $239.30 on Thursday. The firm has a market cap of $35.15 billion, a price-to-earnings ratio of 23.41, a price-to-earnings-growth ratio of 1.14 and a beta of 0.44. The stock’s 50-day moving average is $243.57 and its 200-day moving average is $290.04. Biogen has a one year low of $217.10 and a one year high of $468.55. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.70 and a quick ratio of 1.38.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Banque Pictet & Cie SA lifted its stake in shares of Biogen by 49.2% in the 3rd quarter. Banque Pictet & Cie SA now owns 22,262 shares of the biotechnology company’s stock valued at $6,300,000 after acquiring an additional 7,338 shares during the last quarter. Nordea Investment Management AB increased its holdings in Biogen by 105.4% in the third quarter. Nordea Investment Management AB now owns 913,972 shares of the biotechnology company’s stock valued at $262,000,000 after purchasing an additional 468,973 shares during the period. Brandywine Global Investment Management LLC increased its holdings in Biogen by 22.8% in the second quarter. Brandywine Global Investment Management LLC now owns 49,849 shares of the biotechnology company’s stock valued at $17,261,000 after purchasing an additional 9,268 shares during the period. Arlington Partners LLC increased its holdings in Biogen by 5.9% in the third quarter. Arlington Partners LLC now owns 8,758 shares of the biotechnology company’s stock valued at $2,478,000 after purchasing an additional 488 shares during the period. Finally, CIBC Asset Management Inc increased its holdings in Biogen by 2.3% in the second quarter. CIBC Asset Management Inc now owns 27,601 shares of the biotechnology company’s stock valued at $9,557,000 after purchasing an additional 626 shares during the period. Hedge funds and other institutional investors own 82.61% of the company’s stock.

Biogen Company Profile

Biogen, Inc is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

Recommended Story: Google Finance

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.